Clinical Trial Update: Study of Safety and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH) [Phase 2]

View source ↗

Summary

Phase 2 trial of Tropifexor (LJN452) in non-alcoholic steatohepatitis was terminated; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Steatohepatitis

Drugs mentioned

• Tropifexor

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Non-alcoholic Steatohepatitis (NASH) | Phase 2 | Status: TERMINATED | Results posted: 2021-07-29